Login to Your Account

Other News To Note

Friday, January 20, 2012
• Innovative Targeting Solutions Inc., of Burnaby, British Columbia, initiated a research collaboration allowing Amgen Inc., of Thousand Oaks, Calif., to assess its human antibody technology (HuTARG) for a broader potential collaboration. The mammalian technology generates antibody diversity in vitro via RAG1/RAG2-mediated V(D)J recombination. Terms were not disclosed.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription